Patents Examined by Stephen L. Rawlings
-
Patent number: 11952418Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.Type: GrantFiled: February 12, 2020Date of Patent: April 9, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
-
Patent number: 11952421Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.Type: GrantFiled: October 8, 2015Date of Patent: April 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
-
Patent number: 11926665Abstract: The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.Type: GrantFiled: January 9, 2018Date of Patent: March 12, 2024Assignee: TESARO, INC.Inventors: Dmitri Bobilev, Andrew R. Ferguson, Kristen Anne McEachern, Jing Wang
-
Patent number: 11913025Abstract: Provided are methods of inducing differentiation and/or proliferation of T cells and uses thereof. In the present method, peripheral blood mononuclear cells (PBMCs) isolated from a subject are cultivated with bi-specific antibodies (BsAbs) in a culture medium so as to differentiate the PBMCs into the T cells. Each of the T cells has an anti-tumor antigen moiety and an anti-CD3 moiety on its surface. Also provided are methods and pharmaceutical kits for treating subjects suffering from cancers.Type: GrantFiled: March 29, 2018Date of Patent: February 27, 2024Assignee: Cytoarm Co., LtdInventors: Kuo-Hsiang Chuang, Yi-Jou Chen, Michael Chen
-
Patent number: 11898207Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.Type: GrantFiled: March 28, 2018Date of Patent: February 13, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Yong-Chen Lu, Peter Fitzgerald, Zhili Zheng, Steven A. Rosenberg
-
Patent number: 11820793Abstract: The present inventors discovered that by forming a large immune complex comprising antigens containing two or more antigenic binding units (epitopes) and two or more antigen-binding molecules (for example, antibodies), elimination from the plasma of the antigens containing two or more antigenic binding units can be accelerated. Moreover, they found that by using this characteristic and by further using antigen-binding molecules having an ion-dependent antigen-binding activity, elimination of the antigens can further be accelerated and the above problem can be solved.Type: GrantFiled: August 22, 2018Date of Patent: November 21, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Naoka Hironiwa
-
Patent number: 11795219Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: May 11, 2020Date of Patent: October 24, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Walter Carroll Davidson, Pankaj Gupta, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Jr., Haiguang Xiao, Danlin Yang
-
Patent number: 11779605Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: December 17, 2019Date of Patent: October 10, 2023Assignee: Immatics Biotechnologies GmbHInventors: Gisela Schimmack, Annika Sonntag, Heiko Schuster, Daniel Johannes Kowalewski, Michael Roemer, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Harpreet Singh
-
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
Patent number: 11773182Abstract: The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.Type: GrantFiled: January 5, 2018Date of Patent: October 3, 2023Assignees: The Johns Hopkins University, Institute of Biotechnology CAS, V.V.I.Inventors: Cyril Barinka, Martin G. Pomper, Zora Novakova, Catherine A. Foss -
Patent number: 11723963Abstract: The invention provides a peptide derived from the interleukin-13 receptor ?2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.Type: GrantFiled: September 16, 2019Date of Patent: August 15, 2023Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Hideho Okada, Walter J. Storkus
-
Patent number: 11685788Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: GrantFiled: May 1, 2020Date of Patent: June 27, 2023Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 11684659Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens. Also provided herein are methods of making the vaccine compositions, methods of preparing, and methods of use thereof.Type: GrantFiled: April 21, 2022Date of Patent: June 27, 2023Assignee: NEUVOGEN, INC.Inventors: Bernadette Ferraro, Justin James Arndt, Todd Merrill Binder, Matthias Hundt, Kendall M. Mohler, Jian Yan
-
Patent number: 11684660Abstract: Disclosed are compositions related to synthetic PD-1 peptides, chimeric PD-1 peptides, anti-PD-1 antibodies and methods of treating cancers, autoimmune diseases, and Alzheimer's disease using said peptides or antibodies.Type: GrantFiled: March 28, 2018Date of Patent: June 27, 2023Assignees: OHIO STATE INNOVATION FOUNDATION, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Pravin T. P. Kaumaya, Tanios Bekaii-Saab
-
Patent number: 11680108Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.Type: GrantFiled: October 29, 2019Date of Patent: June 20, 2023Assignee: AVEO Pharmaceuticals, Inc.Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
-
Patent number: 11643454Abstract: Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).Type: GrantFiled: February 10, 2019Date of Patent: May 9, 2023Assignee: BIOASIS TECHNOLOGIES, INC.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 11634486Abstract: Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: GrantFiled: December 22, 2017Date of Patent: April 25, 2023Assignee: Bluefin BioMedicine, Inc.Inventors: Kevin Jefferies, Scott Michael Lonning, Nels Eric Pederson, Jason G. Beaudet, Klarisa Rikova, Aleksandr Tkachev
-
Patent number: 11590170Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.Type: GrantFiled: April 18, 2022Date of Patent: February 28, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Evangelia Kokalaki, Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Biao Ma, Mathieu Ferrari
-
Patent number: 11590168Abstract: Provided by the present invention is a chimeric antigen receptor comprising a co-stimulatory receptor, the chimeric antigen receptor having a structure of scFv(X)-(Y)CD3zeta-2A-(Z); X comprises a tumortargeting antibody or a ligand or receptor capable of specifically binding to a tumor; Y is an intracellular region of the co-stimulatory receptor, and Z is a co-stimulatory receptor that is selected from among ICOS, CD28, CD27, HVEM, LIGHT, CD40L, 4-1BB, OX40, DR3, GITR, CD30, TIMI, SLAM, CD2, CD226. Further provided by the present invention are CAR-T cells that are constructed by means of a recombinant expression vector of the described chimeric antigen receptor, a preparation method therefor and an application thereof. The CAR-T cells described in the present invention significantly improve the tumor-killing abilities and amplification abilities thereof.Type: GrantFiled: December 18, 2020Date of Patent: February 28, 2023Assignee: Shanghai Longyao Biotechnology Inc., Ltd.Inventors: Xuanming Yang, Yangxin Fu, Xin Wang, Shengqin Ye, Fanlin Li, Huihui Zhang
-
Patent number: 11541127Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: GrantFiled: April 13, 2016Date of Patent: January 3, 2023Assignees: Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
-
Patent number: 11498968Abstract: The current invention relates to the combination therapy of an anti-CSF-1R antibody (especially a CSF-1R dimerization inhibitor) in combination with an anti-PD-L1 antibody after PD1/PD-L1 inhibitor treatment failure, corresponding pharmaceutical compositions or medicaments using such combination therapy.Type: GrantFiled: June 11, 2019Date of Patent: November 15, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Michael Cannarile, Anna-Maria Jegg, Francesca Michielin, Carola Ries, Dominik Ruettinger, Martin Weisser